The second study examined the question of whether repairing the ssUV- induced DNA damage by OGG1 in the epidermal keratinocytes, would also present the by-stander effect in the fibroblasts by reducing the release of TNf-a from NHEK. For the test, dermal fibroblasts were grown for 48 hours in materials taken from the ssUV-irradiated NHEK. The ssUV-irradiated NHEK induced more MMP-1 secretion and greater collagen loss compared to direction irradiation of NHDF with the same ssUV dose. The model system was also used to investigate whether OGG1 would be effective in diminishing the detrimental effects of ssUV radiation on the underlying dermis. Treatment of ssUV-irradiated NHEK with OGG1 liposomes for 24 hours suppressed the induction of MMP-1 secretion by NHDF, as well as showed diminished collagen loss.
In conclusion, these results indicate that treatment of dermal fibroblasts and epidermal keratinocytes with OGG1 liposomes enhance DNA repair, reduces MMP-1 and increases collagen levels in the epidermis and the underlying dermis.
AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Remergent DNA Repair Formula and Antioxidant Refoliator both contain Roxomes, liposomes encapsulating OGG1.
About AGI Dermatics
AGI Dermatics is the bio-pharmaceutical laboratory that has led
research of DNA repair of the skin for more than 20 years. Founded by
Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology,
dedicating research and development to DNA repair, solar impact on the
immune system, and cell- signaling in skin. The company's application of
groundbreaking active ingredients and meticulously engineered liposome
delivery systems is validated in controlled clinical studies and published
in dozens of peer-reviewed scientific and medical journals. '/>"/>
| SOURCE AGI Dermatics Copyright©2008 PR Newswire. All rights reserved |